The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

BACKGROUND: While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucas, David M., Alinari, Lapo, West, Derek A., Davis, Melanie E., Edwards, Ryan B., Johnson, Amy J., Blum, Kristie A., Hofmeister, Craig C., Freitas, Michael A., Parthun, Mark R., Wang, Dasheng, Lehman, Amy, Zhang, Xiaoli, Jarjoura, David, Kulp, Samuel K., Croce, Carlo M., Grever, Michael R., Chen, Ching-Shih, Baiocchi, Robert A., Byrd, John C.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880605/
https://www.ncbi.nlm.nih.gov/pubmed/20532179
http://dx.doi.org/10.1371/journal.pone.0010941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880605/
https://www.ncbi.nlm.nih.gov/pubmed/20532179
http://dx.doi.org/10.1371/journal.pone.0010941

Ejemplares similares